levodopa has been researched along with Drug Withdrawal Symptoms in 100 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 33 (33.00) | 18.7374 |
1990's | 32 (32.00) | 18.2507 |
2000's | 26 (26.00) | 29.6817 |
2010's | 8 (8.00) | 24.3611 |
2020's | 1 (1.00) | 2.80 |
Authors | Studies |
---|---|
Jost, WH; Koschel, J; Raeder, V; Ray Chaudhuri, K; Thiel, M; Tönges, L | 1 |
Casier, I; Hantson, P; Jeanjean, A | 1 |
Cannas, A; Fasano, A; Lang, AE; Marrosu, F; Marrosu, MG; Mulas, CS; Solla, P | 1 |
Ablordeppey, E; Taylor, B; Whitman, CB | 1 |
Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
Frisina, PG; Gracies, JM; Hälbig, TD; Koller, WC; Lesser, G; Liang, L; Libow, LS; Neufeld, R; Tarshish, C; Tse, W | 1 |
Ba, M; Kong, M; Liu, Z; Song, L | 1 |
San Luciano, M; Saunders-Pullman, R | 1 |
Cresswell, SA; Evans, AH; Katzenschlager, R; Lawrence, AD; Lees, AJ | 1 |
Man, SP | 1 |
Domino, EF; Jutkiewicz, EM; Ohmura, Y | 1 |
McKeown, MJ; Oishi, MM; Stevenson, JK; Talebifard, P; Ty, E | 1 |
Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
Kleiner-Fisman, G; Lang, AE; Lozano, A; Miyasaki, J; Saint-Cyr, JA | 1 |
Agid, Y; Bejjani, BP; Houeto, JL; Mallet, L; Mesnage, V; Welter, ML | 1 |
Serrano-Dueñas, M | 1 |
Kuno, S; Mizuno, Y; Mizuta, E; Takubo, H | 1 |
Hanyu, N; Hashimoto, T; Tabata, K; Tokuda, T; Yanagisawa, N | 1 |
Mizuno, Y; Shimoda-Matsubayashi, S; Takubo, H | 1 |
Ahmed, SM; Chartisathian, K; Chase, TN; Oh, JD | 1 |
Castro, A; Dapena, MD; Linazasoro, G; Van Blercom, N | 1 |
Al-Din, A; Lily, O | 1 |
Ladha, SS; Shill, HA; Walker, R | 1 |
Ward, C | 1 |
Iyer, SS; Morgan, JC; Sethi, KD | 1 |
Brodsky, MA; Hogarth, P; Nutt, JG | 1 |
Brooks, DJ; Goerendt, IK; Lawrence, AD | 1 |
Douglas, A; Morris, J | 1 |
Mutani, R; Sechi, GP; Tanda, F | 1 |
Bear, G; Casson, I; Durso, R; Foo, SH; Goldstein, M; Khayali, M; Kupersmith, M; Lieberman, A; Neophytides, A | 1 |
Bailey, R; Crisp, E; Jackson, DM; Jenkins, O | 1 |
Armando, I; Clow, A; Glover, V; Sandler, M | 1 |
Goetz, CG; Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
Ghosh, MN; Gopalakrishnan, V; Pillai, NP; Ramaswamy, S | 1 |
Chatel, DM; Dahdal, WY; Franson, KL; Grossberg, GT; Hay, DP; Kotegal, S; Mirza, WU; Neppe, V; Szwabo, PA | 1 |
Collier, TJ; Junn, FS; Sladek, JR; Steece-Collier, K; Yurek, DM | 1 |
Carey, RJ; Huston, JP; Pinheiro-Carrera, M; Tomaz, C | 1 |
Gershteĭn, LM; Kukuev, LA; Sergutina, AV | 1 |
Cetel, M; Guilleminault, C; Philip, P | 1 |
Cape, G | 1 |
González, J; Masana, L; Olivé, JM | 1 |
Fernandez, W; Lees, AJ; Turjanski, N | 1 |
Cheng, FC; Chia, LG; Kuo, JS | 1 |
Angrist, B; Sanfilipo, M; Wolfsohn, R | 1 |
Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
Kornhuber, J; Weller, M | 1 |
Lange, KW; Marsden, CD; Paul, GM; Robbins, TW | 1 |
Kaufman, BS; Young, CC | 1 |
Fuchs, G | 1 |
Barbato, L; Marsden, CD; Monge, A; Nordera, G; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
el-Kadi, AO; Sharif, SI | 1 |
Kobayashi, T; Muneta, S; Saeki, H | 1 |
Horikawa, Y; Iijima, K; Koganei, H; Tanaka, O; Tanaka, S | 1 |
Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
Bonoma, RA; Iwuagwu, CU; Riley, D | 1 |
Galili-Mosberg, R; Melamed, E; Merims, D | 1 |
Chew, EL; Ong, KC; Ong, YY | 1 |
Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A | 1 |
Onofrj, M; Paci, C; Thomas, A | 1 |
Frucht, SJ; Gordon, PH | 1 |
Bunney, WE; Kopanda, RT; Murphy, DL | 1 |
Kruszewska, A; Langwiński, R | 1 |
Timberlake, WH; Vance, MA | 1 |
Laplane, D | 1 |
Bhargava, HN | 1 |
Blum, K; Eubanks, JD; Schwertner, HA; Wallace, JE | 1 |
Bantoutova, I; Kobourova, K; Ovcharov, R | 1 |
Blum, K; Eubanks, JD; Morgan, WW; Schwertner, H; Wallace, JE | 1 |
Colpaert, FC; Laduron, P; Lal, H | 1 |
Kuschinsky, K | 1 |
Heninger, GR; Kleber, HD; Kosten, TR; McDougle, CJ; Palumbo, JM; Price, LH | 1 |
Brown, RG; Jahanshahi, M; Marsden, CD | 1 |
Bonuccelli, U; Corsini, GU; Muratorio, A; Piccini, P | 1 |
James, M; Lange, KW; Marsden, CD; Owen, AM; Paul, GM; Robbins, TW | 1 |
Campbell, N; Evans, C; Franco, K; Pentz, J; Tamburrino, M | 1 |
Carey, RJ | 1 |
Eriksson, T; Oberg, B; Pedersen, SW | 1 |
Lefeber, EJ; Rainer, C; Scheinost, NA | 1 |
Goldswain, PR; Harrison, WB; Reutens, DC | 1 |
Montastruc, JL; Rascol, O; Salachas, F | 1 |
Meltzer, HY; Parsa, MA; Ramirez, LF; Rohr, T | 1 |
Angrist, B; Wolfsohn, R | 1 |
Choi, P; Parrott, A | 1 |
Boyce, S; Jenner, P; Marsden, CD | 1 |
De Cuypere, G; Jannes, C; Remouchamps, A; Tack, E | 1 |
Agid, Y; Bonnet, AM; Javoy-Agid, F; Ruberg, M | 1 |
Kantak, KM; Miczek, KA | 1 |
Gibb, WR | 1 |
Lees, AJ; Poewe, WH; Stern, GM | 1 |
Berman, ML; Tennant, F | 1 |
Greenberg, HS; Hirschorn, KA | 1 |
Lang, AE | 1 |
Golubev, VL; Orlova, OR | 1 |
Iacono, RP; Sandyk, R | 1 |
Gibb, WR; Griffith, DN | 1 |
Maesner, JE | 1 |
Clow, A; Murray, R; Sandler, M; Saunders, JB; Topham, A | 1 |
Feinberg, SS; Feldman, RG; Friedman, JH | 1 |
8 review(s) available for levodopa and Drug Withdrawal Symptoms
Article | Year |
---|---|
Implications of dopaminergic medication withdrawal in Parkinson's disease.
Topics: Amantadine; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 2022 |
Substance abuse and movement disorders.
Topics: Alcoholism; Animals; Apomorphine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substance Withdrawal Syndrome; Substance-Related Disorders | 2009 |
Malignant syndrome in Parkinson's disease: concept and review of the literature.
Topics: Antiparkinson Agents; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Drug-induced seizures in the elderly. Causative agents and optimal management.
Topics: Aging; Anti-Bacterial Agents; Anti-Infective Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Central Nervous System Agents; Histamine H2 Antagonists; Humans; Lactams; Levodopa; Seizures; Substance Withdrawal Syndrome; Theophylline | 1995 |
L-dopa and frontal cognitive function in Parkinson's disease.
Topics: Aged; Dementia; Frontal Lobe; Humans; Levodopa; Mental Processes; Neuropsychological Tests; Parkinson Disease; Prefrontal Cortex; Substance Withdrawal Syndrome | 1993 |
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
Topics: Aged; Carbidopa; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
[Neuroleptic malignant-like syndrome following levodopa withdrawal].
Topics: Aged; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1990 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
8 trial(s) available for levodopa and Drug Withdrawal Symptoms
Article | Year |
---|---|
The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; New York City; Nursing Homes; Parkinson Disease; Severity of Illness Index; Substance Withdrawal Syndrome | 2008 |
Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome | 2011 |
A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence.
Topics: Adult; Breath Tests; Carbidopa; Cocaine; Drug Combinations; Electrocardiography; Humans; Levodopa; Substance Withdrawal Syndrome | 1993 |
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome | 2001 |
Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Substance Withdrawal Syndrome | 1978 |
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction.
Topics: Brain Diseases; Cognition Disorders; Discrimination, Psychological; Female; Frontal Lobe; Humans; Learning; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome | 1992 |
84 other study(ies) available for levodopa and Drug Withdrawal Symptoms
Article | Year |
---|---|
Postoperative hyperthermic syndrome following antiparkinsonian drugs withdrawal: the pitfall of enteral refeeding.
Topics: Aged, 80 and over; Antiparkinson Agents; Diagnosis, Differential; Drug Administration Schedule; Drug Interactions; Enteral Nutrition; Follow-Up Studies; Humans; Intubation, Gastrointestinal; Levodopa; Male; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Postoperative Period; Substance Withdrawal Syndrome | 2013 |
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Anhedonia; Apathy; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2015 |
Levodopa Withdrawal Presenting as Fever in a Critically Ill Patient Receiving Concomitant Enteral Nutrition.
Topics: Aged; Combined Modality Therapy; Enteral Nutrition; Fever; Food-Drug Interactions; Humans; Levodopa; Male; Substance Withdrawal Syndrome | 2016 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum.
Topics: Animals; Blotting, Western; Dopamine Agents; Female; Indicators and Reagents; Levodopa; Movement; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Sympatholytics | 2009 |
Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.
Topics: Affect; Compulsive Behavior; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome | 2010 |
An uncommon adverse effect of levodopa withdrawal in a patient taking antipsychotic medication: neuroleptic malignant-like syndrome.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dopamine Agonists; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndrome | 2011 |
L-DOPA attenuates nicotine withdrawal-induced behaviors in rats.
Topics: Animals; Behavior, Animal; Depression; Dopamine Agents; Levodopa; Male; Motor Activity; Nicotine; Rats; Rats, Sprague-Dawley; Smoking Cessation; Substance Withdrawal Syndrome | 2011 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Topics: Confusion; Depression; Dopamine Agonists; Dysarthria; Electric Stimulation Therapy; Follow-Up Studies; Humans; Levodopa; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome; Subthalamic Nucleus; Time; Treatment Outcome | 2003 |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Topics: Confusion; Depression; Dopamine Agonists; Electric Stimulation Therapy; Follow-Up Studies; Levodopa; Mood Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease; Quality of Life; Social Behavior Disorders; Substance Withdrawal Syndrome; Subthalamic Nucleus; Time; Treatment Outcome | 2003 |
Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients.
Topics: Adult; Aged; Analysis of Variance; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dehydration; Female; Fever; Health Status; Humans; Incidence; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Risk Factors; Substance Withdrawal Syndrome | 2003 |
Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Creatine Kinase; Female; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2003 |
Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Phosphorylation; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substantia Nigra | 2003 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Consciousness Disorders; Dantrolene; Deep Brain Stimulation; Diagnosis, Differential; Diagnostic Errors; Dystonic Disorders; Encephalitis; Female; Fluid Therapy; Foot; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Muscle Relaxants, Central; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tachycardia | 2004 |
Case study: cerebrovascular parkinsonism with levodopa addiction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Female; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance.
Topics: Diagnosis, Differential; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Phytotherapy; Substance Withdrawal Syndrome; Vicia faba | 2005 |
Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
Topics: Aged; Antiparkinson Agents; Confusion; Dantrolene; Deep Brain Stimulation; Dehydration; Dopamine Agents; Drug Monitoring; Electrolytes; Fever; Humans; Leukocyte Count; Levodopa; Magnetic Resonance Imaging; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Nurse's Role; Nursing Assessment; Parkinson Disease; Physical Examination; Substance Withdrawal Syndrome; Time Factors; Urinalysis | 2005 |
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus | 2006 |
Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy.
Topics: Aged; Anger; Antiparkinson Agents; Dopamine Agents; Emotions; Exploratory Behavior; Facial Expression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Personality Tests; Social Perception; Substance Withdrawal Syndrome | 2007 |
It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Fever; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 2006 |
Fatal hyperpyrexia after withdrawal of levodopa.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1984 |
Long-term efficacy of bromocriptine in Parkinson disease.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1980 |
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.
Topics: Animals; Apomorphine; Benserazide; Body Temperature Regulation; Brain; Clonidine; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Male; Mice; Motor Activity; Norepinephrine; Substance Withdrawal Syndrome | 1981 |
Pictet-Spengler condensation products, stress and alcoholism: some clinical overtones.
Topics: Alcoholism; Animals; Carbolines; Chemical Phenomena; Chemistry; Gas Chromatography-Mass Spectrometry; Humans; Isoquinolines; Levodopa; Monoamine Oxidase Inhibitors; Papaverine; Rats; Salsoline Alkaloids; Stress, Physiological; Substance Withdrawal Syndrome; Tetrahydroisoquinolines; Tetrahydropapaveroline | 1982 |
Complications of chronic levodopa therapy: long-term efficacy of drug holiday.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome | 1981 |
L-Dopa induced jumping behaviour in acutely morphinized mice.
Topics: Animals; Humans; Levodopa; Male; Mice; Morphine; Motor Activity; Substance Withdrawal Syndrome | 1981 |
The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing.
Topics: Animals; Dopamine; Drug Administration Schedule; Fetal Tissue Transplantation; Levodopa; Male; Motor Activity; Neurons; Rats; Rats, Inbred F344; Rotation; Substance Withdrawal Syndrome; Time Factors | 1995 |
NMDA antagonist effects on the development of L-dopa behavioral sensitization in rats.
Topics: Animals; Dizocilpine Maleate; Dominance, Cerebral; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substance Withdrawal Syndrome; Synaptic Transmission; Tegmentum Mesencephali | 1995 |
[Pathochemical changes in the motor structures of the brain under the influence of the administration of L-DOPA preparations and their withdrawal (experimental research)].
Topics: Animals; Benserazide; Brain; Brain Chemistry; Drug Combinations; Histocytochemistry; Levodopa; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Time Factors | 1994 |
Dopaminergic treatment of restless legs and rebound phenomenon.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Prospective Studies; Restless Legs Syndrome; Substance Withdrawal Syndrome | 1993 |
Neuroleptic malignant syndrome--a cautionary tale and a surprising outcome.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Antisocial Personality Disorder; Combined Modality Therapy; Critical Care; Dantrolene; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluphenazine; Follow-Up Studies; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Schizoid Personality Disorder; Sick Role; Social Environment; Substance Withdrawal Syndrome | 1994 |
Meperidine and reversible parkinsonism.
Topics: Adult; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Meperidine; Neurologic Examination; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1994 |
The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine; Substance Withdrawal Syndrome | 1993 |
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Topics: Aged; Benserazide; Biogenic Monoamines; China; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal.
Topics: Anesthesia; Antiparkinson Agents; Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Neuromuscular Blocking Agents; Postoperative Complications; Substance Withdrawal Syndrome | 1995 |
[Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance Withdrawal Syndrome | 1997 |
The long-duration action of levodopa may be due to a postsynaptic effect.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Time Factors | 1997 |
The role of dopamine in the expression of morphine withdrawal.
Topics: Adrenergic Agents; Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Antagonists; Hypothermia; Levodopa; Male; Mice; Morphine; Naloxone; Narcotic Antagonists; Oxidopamine; Substance Withdrawal Syndrome | 1998 |
[Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy].
Topics: Aged; Amylases; Diabetic Coma; Disseminated Intravascular Coagulation; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1998 |
[Postoperative respiratory failure resulting from perioperative withdrawal of antiparkinsonian medications].
Topics: Aged; Antiparkinson Agents; Humans; Levodopa; Male; Perioperative Care; Postoperative Complications; Respiratory Insufficiency; Substance Withdrawal Syndrome | 1999 |
Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Confusion; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Nitrophenols; Substance Withdrawal Syndrome; Tolcapone | 2000 |
Is there addiction to levodopa in patients with Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Behavior, Addictive; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Quadriplegia; Substance Withdrawal Syndrome | 2000 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Antiparkinson Agents; Bromocriptine; Creatine Kinase; Diagnosis, Differential; Diagnostic Errors; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 2001 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone | 2001 |
Neuroleptic malignant syndrome in advanced Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Secondary Prevention; Severity of Illness Index; Substance Withdrawal Syndrome | 2001 |
Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man.
Topics: Behavior; Bipolar Disorder; Dopamine; Humans; Levodopa; Norepinephrine; Receptors, Neurotransmitter; Sleep; Substance Withdrawal Syndrome; Tryptophan; Tyrosine | 1977 |
[The effect of reserpine on the morphine abstinence syndrome in mice (author's transl)].
Topics: 5-Hydroxytryptophan; Animals; Drug Antagonism; Humans; Levodopa; Male; Mice; Morphine Dependence; Reserpine; Substance Withdrawal Syndrome | 1979 |
[On some dangerous withdrawals in neurology].
Topics: Anticoagulants; Barbiturates; Central Nervous System Diseases; Humans; Levodopa; Parasympatholytics; Substance Withdrawal Syndrome | 1979 |
Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome.
Topics: Amphetamine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Dronabinol; Humans; Levodopa; Male; Mice; Morphine Dependence; Motor Activity; Naloxone; Substance Withdrawal Syndrome | 1978 |
Suppression of ethanol withdrawal by dopamine.
Topics: Animals; Dopamine; Ethanol; Haloperidol; Humans; Levodopa; Mice; Seizures; Substance Withdrawal Syndrome; Time Factors | 1976 |
Pharmacological analysis of certain mechanisms of morphine addiction.
Topics: Animals; Brain Chemistry; Diphenhydramine; Dopamine; Humans; Levodopa; Lysergic Acid Diethylamide; Male; Methysergide; Morphine Dependence; Norepinephrine; Rats; Reaction Time; Serotonin; Substance Withdrawal Syndrome; Time Factors | 1976 |
Possible role of tetrahydroisoquinoline alkaloids in postalcohol intoxication states.
Topics: Alcoholic Intoxication; Alcoholism; Animals; Brain; Catecholamines; Chlordiazepoxide; Dopamine; Humans; Isoquinolines; Levodopa; Pyrazoles; Rats; Substance Withdrawal Syndrome | 1976 |
Narcotic withdrawal like mouse jumping produced by amphetamine and L-DOPA.
Topics: Amphetamine; Animals; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Fluorometry; Haloperidol; Humans; Levodopa; Male; Mice; Motor Activity; Norepinephrine; Phentolamine; Pimozide; Substance Withdrawal Syndrome | 1975 |
Does chronic morphine treatment induce a supersensitivity of dopamine receptors in rat brain?
Topics: Animals; Apomorphine; Benserazide; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Levodopa; Male; Morphine; Probenecid; Rats; Receptors, Drug; Stereotyped Behavior; Substance Withdrawal Syndrome | 1975 |
Dopaminergic responsivity during cocaine abstinence: a pilot study.
Topics: Adult; Carbidopa; Cocaine; Dopamine Agents; Drug Combinations; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Prolactin; Receptors, Dopamine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1992 |
The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.
Topics: Adult; Aged; Arousal; Attention; Choice Behavior; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Substance Withdrawal Syndrome | 1992 |
Apomorphine in malignant syndrome due to levodopa withdrawal.
Topics: Aged; Apomorphine; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1992 |
Dopaminergic activity and idiopathic edema.
Topics: Adult; Brain; Diuresis; Dopamine; Dyskinesia, Drug-Induced; Edema; Female; Galactorrhea; Haloperidol; Humans; Levodopa; Receptors, Dopamine; Substance Withdrawal Syndrome | 1991 |
Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Drug Tolerance; Functional Laterality; Homovanillic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1991 |
Effects of withdrawal of antiparkinson medication on gait and clinical score in the Parkinson patient.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Disability Evaluation; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Neuroleptic malignant syndrome complicating levodopa withdrawal.
Topics: Aged; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Tranylcypromine; Tryptophan | 1990 |
A pilot trial of levodopa/carbidopa in early cocaine abstinence.
Topics: Adult; Arousal; Carbidopa; Cocaine; Drug Therapy, Combination; Humans; Levodopa; Pilot Projects; Substance Withdrawal Syndrome; Substance-Related Disorders | 1990 |
Illicit drug use in strength athletes.
Topics: Adult; Anabolic Agents; Diagnosis, Differential; Humans; Levodopa; Male; Physical Education and Training; Substance Withdrawal Syndrome | 1989 |
Levodopa addiction. A case study.
Topics: Adult; Dermatitis, Seborrheic; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Muscle Rigidity; Paranoid Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Risk Factors; Substance Withdrawal Syndrome; Substance-Related Disorders | 1988 |
Pathophysiology of L-dopa-induced abnormal involuntary movements.
Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Spiperone; Substance Withdrawal Syndrome; Substantia Nigra; Synapses; Synaptic Transmission | 1985 |
Social, motor, and autonomic signs of morphine withdrawal: differential sensitivities to catecholaminergic drugs in mice.
Topics: Animals; Apomorphine; Autonomic Nervous System; Catecholamines; Clonidine; Cocaine; Dextroamphetamine; Levodopa; Mice; Mice, Inbred Strains; Morphine Dependence; Psychomotor Performance; Reaction Time; Social Behavior; Substance Withdrawal Syndrome | 1988 |
Neuroleptic malignant syndrome in striatonigral degeneration.
Topics: Aged; Corpus Striatum; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Substantia Nigra | 1988 |
Dystonia in Parkinson's disease: clinical and pharmacological features.
Topics: Adult; Aged; Circadian Rhythm; Dose-Response Relationship, Drug; Dystonia; Humans; Injections, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1988 |
Stepwise detoxification from cocaine. A promising regimen.
Topics: Adolescent; Adult; Amantadine; Bromocriptine; Cocaine; Desipramine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Substance Withdrawal Syndrome; Substance-Related Disorders; Tryptophan; Tyrosine | 1988 |
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.
Topics: Aged; Cyproheptadine; Humans; Levodopa; Male; Methysergide; Myoclonus; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1988 |
Sudden confusion with levodopa withdrawal.
Topics: Cognition Disorders; Confusion; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1987 |
[Phenomenon of inverted rotation in spastic torticollis].
Topics: Adult; Brain; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Muscle Spasticity; Receptors, Dopamine; Rotation; Substance Withdrawal Syndrome; Torticollis | 1986 |
Levodopa withdrawal and the neuroleptic malignant syndrome.
Topics: Humans; Levodopa; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndrome | 1986 |
Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.
Topics: Female; Humans; Levodopa; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1986 |
Transient levodopa withdrawal in Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1987 |
Temporary levodopa withdrawal.
Topics: Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 1986 |
The role of salsolinol in alcohol intake and withdrawal.
Topics: Acetaldehyde; Alcoholism; Ethanol; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Substance Withdrawal Syndrome; Time Factors | 1985 |
A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.
Topics: Aged; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1985 |